A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells

Abstract

Background Human epidermal growth factor receptor 2 (HER2) is overexpressed in multiple cancers, which is associated with poor prognosis. Herceptin and other agents targeting HER2 have potent antitumor efficacy in patients with HER2-positive cancers. However, the development of drug resistance adversely impacts the efficacy of these treatments. It is therefore urgent to develop new HER2-targeted therapies. Bispecific antibodies (BsAbs) could guide immune cells toward tumor cells, and produced remarkable effects in some cancers. Methods A BsAb named M802 that targets HER2 and CD3 was produced by introducing a salt bridge and knobs-into-holes (KIHs) packing into the structure. Flow cytometry was performed to determine its binding activity and cytotoxicity. CCK-8, Annexin V/PI staining, western blotting, and ELISA were utilized to study its effect on cell proliferation, apoptosis, the signaling pathways of tumor cells, and the secretion of cytokines by immune cells. Subcutaneous tumor mouse models were used to analyze the in vivo antitumor effects of M802. Results We generated a new format of BsAb, M802, consisting of a monovalent unit against HER2 and a single chain unit against CD3. Our in vitro and in vivo experiments indicated that M802 recruited CD3-positive immune cells and was more cytotoxic than Herceptin in cells with high expression of HER2, low expression of HER2, and Herceptin resistance. Although M802 showed weaker effects than Herceptin on the PI3K/AKT and MAPK pathways, it was more cytotoxic due to its specific recognition of HER2 and its ability to recruit effector cells via its anti-CD3 moiety. Conclusions Our results indicated that M802 exhibited potent antitumor efficacy in vitro and in vivo. M802 retained the function of Herceptin in antitumor signaling pathways, and also recruited CD3-positive immune cells to eliminate HER2-positive tumor cells. Therefore, M802 might be a promising HER2 targeted agent. Electronic supplementary material The online version of this article (10.1186/s13046-019-1354-1) contains supplementary material, which is available to authorized users.

Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs

“…The third approach is the use of synergistic drugs targeting multiple sites that have been shown to be promising in cancer treatment, e.g., using combined biologics Trastuzumab and Pertuzumab antibodies (both of which target different epitopes on the same cancer marker Her2) with marked clinical improvements [88,89]. Further adopting from the biomimicry of bispecific antibodies that can form salt bridges between target cancer cells and the effector leukocytes for increased cytotoxicity [90], there are adoptable applications for Gag inhibitors. Chemically joining different inhibitors of (i) Gag cleavage inhibitors; (ii) Gag allosteric inhibitors (either to cleavage sites or to inhibit compensatory effects); and (iii) existing PIs can be promising modifications.…”

Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy

“…GBR-1302 (ISB 1302) is bispecific ErbB2/CD3 antibody in a Phase 2 clinical trial in patients with metastatic breast cancer resistant to all known therapies (NCT03983395). The bispecific ErbB2/CD3 antibodies BTRC4017A (Phase 1 NCT03448042) and M802 56 are in clinical trials in heavily pre-treated patients. NJH395 and DF1001, which are both in Phase 1 studies (NCT03696771 and NCT04143711, respectively), aim at activating the immune system toward the tumor by delivering a Toll Like Receptor 7 agonist and directing NK cells, respectively.…”

RDGN-based predictive model for the prognosis of breast cancer

“…Apart from molecular typing, tumor DNA sequencing is also an important reference for treatment decision. Patients with germline mutations in BRCA might benefit from PARP inhibitor treatment while patients harboring alterations in ERBB-2 or ESR1 are more likely to develop resistance to standard therapies [8][9][10][11][12][13].…”